TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25045257

Group type: EXPERIMENTAL
Intervention: Bisphosphonates (risedronate 35 mg weekly) for 12 months
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Bisphosphonates along with nutritional supplementation (40 g protein, 600 kcal daily) for the first 6 months
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 79
Study: 22278377

Group type: EXPERIMENTAL
Intervention: Sequential intravenous 5‐FU at 800 mg/m2 for 5 days every 4 weeks followed by weekly PTX at 80 mg/m2
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Sequential S‐1 at 80 mg/m2 for 4 weeks and 2-week rest followed by PTX
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Concurrent intravenous 5‐FU at 600 mg/m2 for 5 days and weekly PTX at 80 mg/m2 every 4 weeks
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Concurrent S‐1 for 14 days and PTX at 50 mg/m2 on days 1 and 8 every 3 weeks
Number of subjects: 161
Study: 20588130

Group type: EXPERIMENTAL
Intervention: Guided imagery audiotape intervention
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 56
Study: 17635557

Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg/day
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study: 16275232

Group type: EXPERIMENTAL
Intervention: Ethinyl E2 plus cyproterone acetate (0.01 mg + 3 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Norethindrone acetate (2.5 mg/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ethinyl E2 plus cyproterone acetate
Number of subjects: 90

Group type: COMPARATOR
Intervention: Norethindrone acetate
Number of subjects: 90
Study: 12109557

Group type: EXPERIMENTAL
Intervention: Individually adjusted footwear with good shock absorbing properties (test group)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Subjects' own, used footwear (control group)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Individually adjusted footwear (test group)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 176
Study: 9974195

Group type: EXPERIMENTAL
Intervention: Aerobic training for 2 months, 30 min sessions, 4 times a week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no aerobic training)
Number of subjects: 20
Study: 7755224

Group type: EXPERIMENTAL
Intervention: 300 mg/d of ursodeoxycholic acid
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: 600 mg/d of ursodeoxycholic acid
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: 1200 mg/d of ursodeoxycholic acid
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1004
Study: 2097894

Group type: EXPERIMENTAL
Intervention: Biologically standardized extract of mites (active therapy)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Saline buffered solution (placebo)
Number of subjects: 58
Study: 6775548

Group type: EXPERIMENTAL
Intervention: nasogastric saline solution alone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: nasogastric saline irrigation with oral mannitol
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: oral mannitol solution without saline
Number of subjects: 62
Study: 31549889

Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg daily plus rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30389818

Group type: EXPERIMENTAL
Intervention: Forward-leaning bikerlike position
Number of subjects: 80
Study: 27090392

Group type: EXPERIMENTAL
Intervention: Elevated F2-isoprostanes
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: HRV parameters (SDNN, VLF, LF, total power)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: F2-isoprostanes
Number of subjects: 78
Study: 26556080

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (cycling training at 70% of maximal intensity for 40 min/d, 3 d/wk for 3 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (health education)
Number of subjects: 50
Study: 23684438

Group type: EXPERIMENTAL
Intervention: 13 g ground flaxseed
Number of subjects: 25
Study: 21566232

Group type: EXPERIMENTAL
Intervention: NeuroFlo treatment
Number of subjects: 515

Group type: COMPARATOR
Intervention: Standard medical management (control)
Number of subjects: 515
Study: 19703665

Group type: EXPERIMENTAL
Intervention: NanoGreens vegetable supplement drink for 90 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 16776704

Group type: EXPERIMENTAL
Intervention: Rizatriptan plus trimebutine (10 mg rizatriptan + 200 mg trimebutine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rizatriptan alone
Number of subjects: 40
Study: 15359672

Group type: EXPERIMENTAL
Intervention: Auditory condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both conditions
Number of subjects: 0
Study: 10671921

Group type: EXPERIMENTAL
Intervention: Axillary node clearance
Number of subjects: 466

Group type: COMPARATOR
Intervention: Axillary node sample
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Axillary node sample with radiotherapy
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Axillary node sample without radiotherapy
Number of subjects: 466
Study: 9611401

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients (European)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients with neuropathy (European)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control subjects (European)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: North African insulin-dependent diabetic patients
Number of subjects: 174

Group type: COMPARATOR
Intervention: North African control subjects
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Presence of restricted allele in European diabetic individuals
Number of subjects: 174
Study: 8406644

Group type: EXPERIMENTAL
Intervention: Amphotericin B (AMB) 1 mg/kg body weight on alternate days, starting with 0.05 mg/kg on the first day, total dose of 20 mg/kg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sodium stibogluconate (SAG) 20 mg/kg body weight, im daily for 30 days
Number of subjects: 150
Study: 3534899

Group type: EXPERIMENTAL
Intervention: 150 mg maprotiline and 9 mg haloperidol per day (for the first six days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Monotherapy with maprotiline
Number of subjects: 28
Study: 31412815

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Screen time
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: MVPA
Number of subjects: 1068
Study: 30220648

Group type: EXPERIMENTAL
Intervention: BFF MDI 320/10 µg
Number of subjects: 2389

Group type: EXPERIMENTAL
Intervention: BFF MDI 160/10 µg
Number of subjects: 2389

Group type: COMPARATOR
Intervention: FF MDI
Number of subjects: 2389
Study: 26554869

Group type: EXPERIMENTAL
Intervention: High-expectation provider communication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 0

Group type: COMPARATOR
Intervention: High expectation vs Neutral expectation
Number of subjects: 0
Study: 25344737

Group type: EXPERIMENTAL
Intervention: Flotation tank treatment
Number of subjects: 65

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 65
Study: 22733065

Group type: EXPERIMENTAL
Intervention: 100 mg intravenous oseltamivir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg intravenous oseltamivir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg intravenous oseltamivir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 0
Study: 20815736

Group type: EXPERIMENTAL
Intervention: Oseltamivir started within 12 hours of symptom onset
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Oseltamivir started within 24 hours of symptom onset
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Oseltamivir started within 24 hours of symptom onset in unvaccinated children
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study: 17218362

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) 250 mg, 3 doses, 8 hours apart
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 15897554

Group type: EXPERIMENTAL
Intervention: Azacitidine treatment
Number of subjects: 191

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 191
Study: 12232483

Group type: EXPERIMENTAL
Intervention: Surgery with total mesorectal excision for T1/2 N0 rectal cancers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant radiochemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term pre-operative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term neoadjuvant radiochemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local excision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional radiochemotherapy
Number of subjects: 0
Study: 9534112

Group type: EXPERIMENTAL
Intervention: Experimental cooperative learning programme
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control classrooms
Number of subjects: 24
Study: 7663010

Group type: EXPERIMENTAL
Intervention: Serum levels of intercellular adhesion molecule-1 at diagnosis in Hodgkin's disease patients
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Serum levels of intercellular adhesion molecule-1 in complete remission
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Serum levels of intercellular adhesion molecule-1 in patients with advanced disease who attained complete remission
Number of subjects: 104

Group type: COMPARATOR
Intervention: Serum levels of intercellular adhesion molecule-1 in patients who failed to attain complete remission
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Correlation of serum levels of intercellular adhesion molecule-1 with clinical features
Number of subjects: 104
Study: 2503895

Group type: EXPERIMENTAL
Intervention: Daonil (Hoechst)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glycomin (Lennon)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Melix (Lagamed)
Number of subjects: 18
Study: 782976

Group type: EXPERIMENTAL
Intervention: Vaccine A (with galactose)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Vaccine B (without galactose)
Number of subjects: 173
Study: 30871801

Group type: EXPERIMENTAL
Intervention: DBS ON
Number of subjects: 10
Study: 26848182

Group type: EXPERIMENTAL
Intervention: Iron sulfate (oral)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Iron sucrose (intravenous)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (non-inflamed subjects)
Number of subjects: 72
Study: 25096309

Group type: EXPERIMENTAL
Intervention: 1500 mg/day oral glucosamine sulphate
Number of subjects: 70

Group type: COMPARATOR
Intervention: Home exercise program for 6 months
Number of subjects: 70
Study: 23820157

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 259
Study: 21401690

Group type: EXPERIMENTAL
Intervention: Clinical context (short stem suggestive of cardiac valvular diagnoses)
Number of subjects: 159

Group type: COMPARATOR
Intervention: No clinical history
Number of subjects: 159
Study: 17511191

Group type: EXPERIMENTAL
Intervention: General anesthesia (for women)
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anesthesia (for men)
Number of subjects: 120
Study: 15863491

Group type: EXPERIMENTAL
Intervention: 50% oxygen
Number of subjects: 52

Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 52
Study: 12220941

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 10
Study: 10463374

Group type: EXPERIMENTAL
Intervention: Imipramine (235 mg/day)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mirtazapine (77 mg/day)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 107
Study: 7886982

Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 2791174

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.375%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.25%
Number of subjects: 12
Study: 698167

Group type: EXPERIMENTAL
Intervention: Small intakes of alcohol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isoenergetic meal of food plus alcohol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isoenergetic meal of food
Number of subjects: 10
Study: 31274485

Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg at induction of anesthesia)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (no furosemide)
Number of subjects: 56
Study: 27984188

Group type: EXPERIMENTAL
Intervention: 579 kJ (138 kcal) liquid meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 828 kJ (198 kcal) liquid meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1776 kJ (424 kcal) liquid meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4188 kJ (1001 kcal) liquid meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-energy meals
Number of subjects: 10
Study: 24916954

Group type: EXPERIMENTAL
Intervention: High-fidelity manikin simulator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fidelity manikin simulator
Number of subjects: 0
Study: 23176897

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 21486552

Group type: EXPERIMENTAL
Intervention: Sankang Capsule
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Rhodiola Rosea Capsule
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Shenqi Pollen Capsule
Number of subjects: 543

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 543
Study: 19271173

Group type: EXPERIMENTAL
Intervention: Yixuesheng capsule (YXS) combined with recombination human erythropoietin (RHE)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Recombination human erythropoietin (RHE) alone
Number of subjects: 65
Study: 16982228

Group type: EXPERIMENTAL
Intervention: Contraceptive patch (EE 20 microg/day and norelgestromin 150 microg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral contraceptive (EE 35 microg and norgestimate 250 microg)
Number of subjects: 24
Study: 15208650

Group type: EXPERIMENTAL
Intervention: Amifostine (1000 mg/day during conditioning)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 60
Study: 12463322

Group type: EXPERIMENTAL
Intervention: Mild asphyxia group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Moderate asphyxia group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study: 9865704

Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study: 7631644

Group type: EXPERIMENTAL
Intervention: 2 mg/kg cocaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1696671

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of Digoxin and Quinapril
Number of subjects: 19
Study: 375687

Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 36
Study: 30946757

Group type: EXPERIMENTAL
Intervention: Fermented milk product containing Bifidobacterium lactis CNCM I‐2494 (FMP)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 125
Study: 27889307

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TA) 15 mg/kg (Group B)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TA) 10 mg/kg (Group C)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TA) 30 mg/kg (Group A)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No Tranexamic Acid (Group D)
Number of subjects: 180
Study: 25894177

Group type: EXPERIMENTAL
Intervention: Dextrose in water plus insulin infusion (group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dextrose in water infusion (group 2)
Number of subjects: 120
Study: 24113621

Group type: EXPERIMENTAL
Intervention: Selective axillary dissection (SAD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Complete axillary lymph node dissection (ALND)
Number of subjects: 60
Study: 21248295

Group type: EXPERIMENTAL
Intervention: Blood lead exposure
Number of subjects: 3941

Group type: COMPARATOR
Intervention: Creatinine-based MDRD and CKD-EPI equations
Number of subjects: 3941
Study: 19170462

Group type: EXPERIMENTAL
Intervention: Traditional behavioral couple therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrative behavioral couple therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less distressed couples
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderation analyses
Number of subjects: 0
Study: 17588810

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) treatment for one month
Number of subjects: 14
Study: 15572757

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 5213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5213
Study: 11488550

Group type: EXPERIMENTAL
Intervention: Physical activity program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 9692434

Group type: EXPERIMENTAL
Intervention: Endoscopic technique (group A, n = 54)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Traditional technique (group B, n = 58)
Number of subjects: 112
Study: 7843574

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation letter providing treatment recommendations
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control physicians (no psychiatric consultation letter)
Number of subjects: 73
Study: 3048533

Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate
Number of subjects: 45

Group type: COMPARATOR
Intervention: 2% sodium tetradecyl sulphate (STD)
Number of subjects: 45
Study: 30740133

Group type: EXPERIMENTAL
Intervention: Arm swing exercise (ASE) training for 3 months, 30 minutes/day, 3 days/week
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Arm swing exercise (ASE) training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (maintained daily routine activities without regular exercise)
Number of subjects: 50
Study: 28431800

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29106100

Group type: EXPERIMENTAL
Intervention: N2O/O2 50/50 mixture
Number of subjects: 147

Group type: COMPARATOR
Intervention: 50% oxygen in air (placebo)
Number of subjects: 147
Study: 24990423

Group type: EXPERIMENTAL
Intervention: 1.5 kcal/mL enteral nutrition solution
Number of subjects: 112

Group type: COMPARATOR
Intervention: 1.0 kcal/mL enteral nutrition solution
Number of subjects: 112
Study: 22798383

Group type: EXPERIMENTAL
Intervention: Group 1: 1.10 mL/kg for men and women
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Group 2: men 1.10 mL/kg, women 0.99 mL/kg
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 207
Study: 20558286

Group type: EXPERIMENTAL
Intervention: Natural kale extract
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 22
Study: 17506931

Group type: COMPARATOR
Intervention: Soya nut diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Soya protein diet
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Control diet (DASH diet)
Number of subjects: 42
Study: 15734772

Group type: EXPERIMENTAL
Intervention: Hand-held steel paddle electrodes
Number of subjects: 201

Group type: COMPARATOR
Intervention: Adhesive patch electrodes
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Biphasic shocks
Number of subjects: 201

Group type: COMPARATOR
Intervention: Monophasic shocks
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Cross-over from monophasic to biphasic shock
Number of subjects: 201

Group type: COMPARATOR
Intervention: Patch electrodes after cross-over
Number of subjects: 201
Study: 12390611

Group type: EXPERIMENTAL
Intervention: 1 g intravenous dipyrone
Number of subjects: 74

Group type: COMPARATOR
Intervention: 10 mL 0.9% physiological saline (placebo)
Number of subjects: 74
Study: 10458683

Group type: EXPERIMENTAL
Intervention: Radical treatment
Number of subjects: 451

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 451
Study: 8928632

Group type: EXPERIMENTAL
Intervention: 200‐ms 1‐kHz tones at 40 dB HL
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 200‐ms 1‐kHz tones at 50 dB HL
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 200‐ms 1‐kHz tones at 60 dB HL
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 200‐ms 1‐kHz tones at 65 dB HL
Number of subjects: 6
Study: 2214124

Group type: EXPERIMENTAL
Intervention: Oral ranitidine (0.4 mg.kg‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intramuscular ranitidine (0.1 mg.kg‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Apple juice (control group)
Number of subjects: 30
Study: 656293

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Prednisone and Prednisolone
Number of subjects: 35
Study: 31351121

Group type: EXPERIMENTAL
Intervention: Health coaching and disease-management services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 28072611

Group type: EXPERIMENTAL
Intervention: Baby Shampoo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Povidone-Iodine (PI)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Isopropyl Alcohol (IA)
Number of subjects: 42